Randomized trial of high-dose epirubicin and cyclophosphamide X 3 supported by peripheral blood progenitor cells versus anthracycline and cyclophosphamide X 4 followed by cyclophosphamide, methotrexate and 5-fluorouracil X 3 as adjuvant treatment for high risk operable stage II and stage III breast cancer in premenopausal and young postmenopausal (less than or equal to 65 yrs) patients
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Antineoplastics; Cyclophosphamide; Cyclophosphamide; Doxorubicin; Epirubicin; Fluorouracil; Mesna; Methotrexate; Tamoxifen
- Indications Breast cancer; Early breast cancer
- Focus Therapeutic Use
- 04 Apr 2013 Biomarkers information updated
- 20 Jul 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.
- 20 Jul 2012 Additional trial location (USA) added as reported by ClinicalTrials.gov.